Publications by authors named "Kate Bendall"

Claim this Profile
T
Tracking a Medicine's Regulatory Risk Management Commitments Provides Better Transparency and Oversight.
Simon Ingate, Kate Bendall, Christopher Long, Kevin Fetterman, Marie Liles-Burden

Ther Innov Regul Sci· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The use of granulocyte colony stimulating factor (G-CSF) and management of chemotherapy delivery during adjuvant treatment for early-stage breast cancer--further observations from the IMPACT solid study.
Johanna Mäenpää, Ioannis Varthalitis, Frans Erdkamp, Andreas Trojan, Krzysztof Krzemieniecki, Kate Bendall

Breast· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
External validation of a risk model of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma.
Matthias Schwenkglenks, Kate Louise Bendall, Alena M Pfeil, Zsolt Szabo, Ruth Pettengell

Leuk Lymphoma· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
Pieternella Lugtenburg, Antonio Salar Silvestre, Francesca G Rossi, Lucien Noens, Wanda Krall, Kate Bendall

Clin Lymphoma Myeloma Leuk· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic costs of chemotherapy-induced febrile neutropenia among patients with non-Hodgkin's lymphoma in European and Australian clinical practice.
Derek Weycker, Aurelie Danel, Anne Marciniak, Kate Bendall, Michael Lipsitz

BMC Cancer· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Importance of granulocyte colony-stimulating factor prophylaxis in therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone given every 14 days for diffuse large B-cell lymphoma in routine clinical practice.
Hans E Johnsen, Corrine Haioun, Pieternella J Lugtenburg, Antonio Salar, Ulrich Jaeger, Kate Bendall

Leuk Lymphoma· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice.
Antonio Salar, Corinne Haioun, Francesca G Rossi, Ulrich Duehrsen, Ruth Pettengell, Kate Bendall

Leuk Res· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma.
Ruth Pettengell, Hans E Johnsen, Pieternella J Lugtenburg, Antonio Salar Silvestre, Ulrich Dührsen, Kate Bendall

Support Care Cancer· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of a guideline-based composite outcome assessment tool for asthma control.
Sally Spencer, Bhabita Mayer, Kate L Bendall, Eric D Bateman

Respir Res· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis